You are here: Industry Insights > antibodies

News List

UK researchers engineer antibodies from llamas against Covid-19 pharmaceutical-technology
July 15, 2020
Researchers from the Rosalind Franklin Institute, Oxford University, Diamond Light Source and Public Health England in the UK have engineered antibodies obtained from llamas against Covid-19.
Neutralizing antibodies in the battle against COVID-19 worldpharmanews
July 10, 2020
An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies.
Quansys Biosciences Releases Multiplex Human Serological SARS-CoV-2 americanpharmaceuticalreview
April 20, 2020
Quansys Biosciences has released their SARS-CoV-2 Human IgG(4-plex) enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of SARS-CoV-2 reactive IgG class antibodies in human serum and plasma.
GSK buys stake in Vir Biotechnology in search of Covid-19 therapies pharmaceutical-technology
April 08, 2020
GlaxoSmithKline (GSK) has agreed to invest $250m in Vir Biotechnology for the research and development (R&D) of antibodies to treat Covid-19 infection.
Tsinghua and partners to develop neutralising antibodies against COVID-19 pharmaceutical-business-review
April 03, 2020
Tsinghua University has joined forces with 3rd People’s Hospital of Shenzhen and Brii Biosciences (Brii Bio) to develop neutralising antibodies against COVID-19 (novel coronavirus).
Beckman Coulter Announces Test Development for Coronavirus Antibodies americanpharmaceuticalreview
April 02, 2020
In response to the global COVID-19 pandemic, Beckman Coulter is developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2.
Regeneron identifies several antibodies against Covid-19 pharmaceutical-technology
March 19, 2020
Regeneron Pharmaceuticals has announced the identification of hundreds of fully human antibodies against Covid-19, caused by the novel coronavirus.
ImmunoPrecise uses PolyTope mAb Therapy for Covid-19 pharmaceutical-technology
March 16, 2020
ImmunoPrecise Antibodies is set to use PolyTope mAb Therapy approach for the development of a universal COVID-19 therapy.
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Wuxi Biologics
February 26, 2020
WuXi Biologics and Vir Biotechnology, Inc. announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Resp
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus PharmaSources/Wuxi Biologics
January 29, 2020
WuXi Biologics has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.

Previous page 1 2 3 4 5 6 Next page